Skip to main content
. 2018 Feb 14;36(11):1073–1079. doi: 10.1200/JCO.2017.76.5719

Fig 1.

Fig 1.

CONSORT diagram of Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial update according to estrogen receptor (ER) status of the ILRR. CT, chemotherapy; ILRR, isolated locoregional recurrence; LFU, lost to follow-up; no CT, no chemotherapy.